The Europe viral inactivation market was valued at USD 135.26 million in 2022 and is estimated to be growing at a CAGR of 12.1% and worth USD 239.44 million by 2027.
The increasing prevalence of chronic diseases among European countries is one of the key factors propelling the European viral inactivation market growth. Chronic diseases such as cancer, autoimmune diseases, and others are the main reason for the increased mortality rate in the European region. For instance, an estimated 80% of deaths in the European region are due to chronic diseases. Furthermore, viral inactivation processes are used in manufacturing various drugs, including cancer, to decontaminate the drugs by removing any viruses that may develop during the production of the drugs, helping reduce the mishaps caused by contaminated drugs.
The growing usage of viral inactivation in bioprocessing is another major factor promoting the European market growth. Viral inactivation is the primary step for the safety of biotherapeutic products. While manufacturing a biological product for various diseases, there is a risk of the sample being contaminated by a virus, which disturbs the process of manufacturing the drug or biological products. Such drawbacks can be avoided using viral inactivation methods, leading to demand for market growth. Viral contamination may occur in vaccines, plasma products, recombinant protein treatments, and cell-based therapeutics that use cell production of biologics.
Furthermore, the rising number of innovative drugs and increasing research and development activities in the life science industry are expected to boost the growth rate of the European market. Furthermore, the growing funding for the pharmaceutical and biotechnology industries is expected to fuel Europe's market’s growth rate. In recent years, the demand for gene therapies has demand owing to the effective use of the drug for fast recovery. As a result, several clinical trials are going on to formulate the desired drugs that need viral inactivation during development. Viral inactivation is also used in the manufacturing of vaccines. If the viral inactivation process is not present in the vaccination process, the vaccine may get contaminated and be difficult to use for medical purposes.
On the other end, the high costs associated with developing viral inactivation products are majorly hampering the European market growth. In addition, the scarcity of skilled professionals and unfavorable reimbursement policies are hindering the growth rate of the European market.
This research report on the Europe Viral Inactivation Market has been segmented and sub-segmented into the following categories:
By End User:
Geographically, the European region had the second biggest share in the worldwide market in 2021. The European market is expected to showcase a prominent CAGR during the forecast period. The growing R&D activities around the development of vital inactivation methods for various samples primarily drive the growth of the European market. For instance, during the COVID-19 pandemic, a new viral inactivation method has been introduced in Europe to stabilize the viral RNA when the samples or collection is used for IVD procedures or during transportation.
Germany led the European market in 2021 and is expected to hold a strong foothold in the European market during the forecast period. The German government imposed strict rules for various viral inactivation methods. Blood transfusion plays a significant role in the medical sector, where the blood transferred from one person to another cannot contain any viruses as it could result in diseases and even death. Therefore, in the blood transfusion process, healthcare providers or workers check the donor blood for the absence or presence of a virus, which is used for different purposes. As a result, viral inactivation methods keep the donor blood safe without any virus for a certain period. As a result, the virus inactivation market has high demand in this region during the forecast period.
During the forecast period, the UK market is expected to register a noteworthy CAGR in the European market. In the UK, the growing number of laboratories for researching various viral inactivation methods is the primary factor for the market's growth. In addition, during the COVID-19 pandemic, researchers have increased activity on developing several viral inactivations to reduce the spread of the coronavirus disease.
KEY MARKET PLAYERS:
Companies such as Clean Cells, Charles River Laboratories International Inc, Danaher Corporation, Merck KGaA, Parker Hannifin, Red Source Technologies, Sartorius AG, SGS S.A, Texcell Inc, Viral Inactivated Plasma Systems SA, and WuXi Pharma Tech Inc. are playing a leading role in the European viral inactivation market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com